NorthWest Biotherapeutics Inc (NWBO)

[gnawkz]

I have read through most of the current debate regarding the make up of psuedos vs rapids progression patients in the 55 expanded access trial.

I was under the impression that if a patient was diagnosed to be a psuedo progressor, they would be moved to the 72 patient sub-arm of the current Phase III trial. Considering the fact that a majority of the patients in the 55 expanded access trial was enrolled in 2012, would that not imply most of the patients are true rapid progressors vs psuedo progressors?

Are there other complexities involved that would make the categorization of patients difficult?

Having pseudoprogression does not disqualify a patient from the Phase III trial. Thus, from that, would it not be safe to assume the majority of the patients in the expanded access arm is made up of true rapid progressors. Sure a few would still fall through the cracks, but not enough to make the current Median OS irrelevant.